Menu
January 8th, 2022
Cypre and Charles River announce the launch of the Cypre 30 PDX Panel for high-content screening of targeted and immunotherapy.
November 4th, 2021
Cypre participates in Endpoints Webinar sponsored by Charles River titled “Changing the game: An examination of cutting-edge novel oncology screening tools.”
November 10th, 2021
Cypre and Charles River present poster #943 at the society of immunotherapy conference (sitc): “3D in vitro tumor model platform rapidly assays immunotherapy efficacy with high content imaging and downstream phenotypic changes with flow cytometry and cytokine analysis.”
May 12, 2021
Cypre presents at the SelectScience® Virtual Cancer and Immunology Research Summit 2021 with Charles River highlighting our 3d tumor model platform for PDX in vitro modeling and cancer drug screening. View summit.
April 13, 2021
Cypre presents webinar with Charles River highlighting the synergy of our platform with pdx models for anticancer and immunotherapy drug screening. Watch webinar.
April 10, 2021
Cypre presents poster #3184 with Charles River at the AACR Annual Meeting 2021. View poster.
January 28, 2021
Cypre announces strategic partnership with Charles River for oncology and immuno-oncology drug discovery screening services. View press release.
September 2020
Cypre initiates validation on additional patient-derived solid tumors with its 3D tumor model platform.
March, 2020
Cypre validates its 3D tumor model platform with patient-derived NSCLC for immunotherapy screening.
July, 2019
Cypre completes several additional pilots with top pharmaceuticals, biotechs and drug discovery providers.
April, 2019
Cypre presents data in an oral mini-symposium presentation at AACR 2019 in collaboration with Genentech. View abstract.
February, 2019
Cypre presents poster at SLAS showcasing synergy of 3D hydrogel technology with high content analysis in collaboration with Molecular Devices.
January, 2019
Cypre 3D Hydrogel Technology short-listed as one of The Top Drug Discovery Tools of 2018 by SelectScience.
January, 2019
Cypre publishes peer-reviewed manuscript in Molecular Cancer Therapeutics in collaboration with Cedars Sinai Medical Center, demonstrating ex vivo growth and drug assays using patient-derived tumors. View abstract.
January, 2018
Cypre invited to speak at Hanson-Wade’s Tumor Models San Francisco Conference. View event.
February, 2017
Cypre receives seed funding.
April, 2016
Cypre and Cedars-Sinai Medical Center sign collaboration agreement to assay patient tumors with drug compounds in Cypre 3D Platform.
January, 2016
Cypre founded and joins MBC BioLabs (formerly QB3@953), San Francisco’s premier biotech incubator.